Mark M. Smits

Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial

C.A.J. van Beers, J. Hans DeVries, Susanne J. Kleijer et al. · The Lancet Diabetes & Endocrinology · 2016 · 377 citations

Type 1, Diabetes Management, Health Policy +5

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

Erik J.M. van Bommel, Marcel H.A. Muskiet, Michaël J.B. van Baar et al. · Kidney International · 2019 · 331 citations · Full text

Metabolic Syndrome, Diabetes Management, Renal Function +13

Nonalcoholic Fatty Liver Disease Is Related to Nonalcoholic Fatty Pancreas Disease

Erwin-Jan M. van Geenen, Mark M. Smits, T.C.M.A. Schreuder et al. · Pancreas · 2010 · 176 citations

Non‐alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: Results of a <scp>US</scp> national survey in three ethnic groups

Mark M. Smits, George N. Ioannou, Edward J. Boyko et al. · Journal of Gastroenterology and Hepatology · 2013 · 141 citations

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial

Mark M. Smits, Lennart Tonneijck, Marcel H.A. Muskiet et al. · Diabetologia · 2016 · 136 citations · Full text